NextCell applies for prediction methodology patent

The stem cell company NextCell Pharma AB ("NXTCL") has submitted another patent application. This time regarding a method for predicting if a specific patient is susceptible to treatment with the drug candidate ProTrans.

Since the beginning of 2017, NXTCL has performed preclinical experiments in parallel with the ongoing clinical trial with ProTrans, for the treatment of diabetes. The purpose of these experiments was in part to predict, in advance, whether ProTrans treatment should be beneficial for a particular patient.

The patent application describes how to isolate the patient's immune cells from a single blood sample and thereafter, stimulate and activate these cells in the laboratory. This is to simulate an inflammatory and / or autoimmune attack. ProTrans (stem cells) are then exposed to the patient's activated immune cells which will affect or be affected by the ProTrans stem cells in various ways. A number of analyzes are performed to measure the interaction between the patient's immune cells and ProTrans to estimate how efficacious a ProTrans treatment should be for a particular patient with a particular disorder.

The NXTCL selection and prediction algorithms ensure that the most potent stem cells are selected to produce ProTrans (selection) and that only those patients who benefit from the treatment are recommended to be treated with ProTrans (prediction).

The work that now has materialized into a patent application started as part of NXTCL's preclinical work in renal transplantation and is intended as a method of tailoring the treatment. Only patients benefiting from treatment shall receive ProTrans.

NXTCL is focusing on type 1 diabetes and the ongoing clinical trial with ProTrans. The company also seek collaborations to evaluate ProTrans for the treatment of other diseases and conditions, where renal transplant is an option.

This information is the information that NextCell Pharma AB is required to disclose under the EU Market Abuse Regulation. The information was provided by the below contact person for publication on 3rd of July 2018.

Stay up to date with the latest development in NextCell Pharma

LinkedIn: https://www.linkedin.com/company/15255207/

Twitter: https://twitter.com/NextCellPharma

For more information about NextCell Pharma AB, please contact:

Mathias Svahn, CEO

Leo Groenewegen, CFO

Phone: 08-735 5595

E-mail: info@nextcellpharma.com

www.nextcellpharma.com

About NextCell Pharma AB:

Stem cells are expected to change the way how many of today's life-threatening diseases are treated. NextCell Pharma AB develops ProTrans, a drug candidate consisting of stem cells for the primary treatment of autoimmune and inflammatory diseases as well as for use in kidney transplants. ProTrans consists of selected stem cells derived from the umbilical cord tissue with NextCell Pharma AB's proprietary method. In addition, the company has a service called Cellaviva, Sweden's first and only IVO-approved stem cell bank for the family-saving of stem cells from umbilical cord blood and umbilical cord tissue.

Subscribe

Documents & Links